Cargando…
Prevalence, severity, and risk factor of breakthrough infection after vaccination with either the Covaxin or the Covishield among healthcare workers: A nationwide cross-sectional study
BACKGROUND AND AIMS: The coronavirus disease-2019 (COVID-19) pandemic has grappled the entire globe since the beginning of 2020. In India, two vaccines were released in January 2021, the Covaxin® and the Covishield™. However, despite vaccination, many breakthrough infections were reported during the...
Autores principales: | Krishna, Bhavya, Gupta, Anju, Meena, Kaushal, Gaba, Astha, Krishna, Shreya, Jyoti, Ruchika, Aeron, Neha, Prashanth, Shruti, Samriti, Ganapathy, Usha |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer - Medknow
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9438823/ https://www.ncbi.nlm.nih.gov/pubmed/36060166 http://dx.doi.org/10.4103/joacp.joacp_436_21 |
Ejemplares similares
-
“Covishield and Covaxin” – India's contribution to global COVID-19 pandemic
por: Raina, Sunil Kumar, et al.
Publicado: (2021) -
Immunogenic and reactogenic efficacy of Covaxin and Covishield: a comparative review
por: Das, Swarnali, et al.
Publicado: (2022) -
Comparison of in-hospital COVID-19 related outcomes between COVISHIELD and COVAXIN recipients
por: Suri, Tejas M., et al.
Publicado: (2022) -
Adverse effects after first and second dose of covishield and covaxin: A longitudinal study
por: Mittal, Amit, et al.
Publicado: (2022) -
2371. A study to describe the pattern of cutaneous adverse effects of COVID-19 vaccines (Covishield and Covaxin )
por: Mitra, Debdeep, et al.
Publicado: (2023)